U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Blepharospasm

MedGen UID:
599
Concept ID:
C0005747
Disease or Syndrome
Synonym: Blepharospasms
SNOMED CT: Spasm of eyelids (59026006); Blepharospasm (spasm of eyelid) (59026006); Blepharospasm (59026006)
 
HPO: HP:0000643

Definition

A focal dystonia that affects the muscles of the eyelids and brow, associated with involuntary recurrent spasm of both eyelids. [from HPO]

Conditions with this feature

Pigmentary pallidal degeneration
MedGen UID:
6708
Concept ID:
C0018523
Disease or Syndrome
Pantothenate kinase-associated neurodegeneration (PKAN) is a type of neurodegeneration with brain iron accumulation (NBIA). The phenotypic spectrum of PKAN includes classic PKAN and atypical PKAN. Classic PKAN is characterized by early-childhood onset of progressive dystonia, dysarthria, rigidity, and choreoathetosis. Pigmentary retinal degeneration is common. Atypical PKAN is characterized by later onset (age >10 years), prominent speech defects, psychiatric disturbances, and more gradual progression of disease.
Deficiency of ferroxidase
MedGen UID:
168057
Concept ID:
C0878682
Disease or Syndrome
Aceruloplasminemia is characterized by iron accumulation in the brain and viscera. The clinical triad of retinal degeneration, diabetes mellitus (DM), and neurologic disease is seen in individuals ranging from age 30 years to older than 70 years. The neurologic findings of movement disorder (blepharospasm, grimacing, facial and neck dystonia, tremors, chorea) and ataxia (gait ataxia, dysarthria) correspond to regions of iron deposition in the brain. Individuals with aceruloplasminemia often present with anemia prior to onset of DM or obvious neurologic problems. Cognitive dysfunction including apathy and forgetfulness occurs in more than half of individuals with this condition.
Deficiency of aromatic-L-amino-acid decarboxylase
MedGen UID:
220945
Concept ID:
C1291564
Disease or Syndrome
Aromatic L-amino acid decarboxylase deficiency (AADCD) is an autosomal recessive inborn error in neurotransmitter metabolism that leads to combined serotonin and catecholamine deficiency (Abeling et al., 2000). The disorder is clinically characterized by vegetative symptoms, oculogyric crises, dystonia, and severe neurologic dysfunction, usually beginning in infancy or childhood (summary by Brun et al., 2010).
Epilepsy, familial adult myoclonic, 2
MedGen UID:
375031
Concept ID:
C1842852
Disease or Syndrome
Familial adult myoclonic epilepsy-2 (FAME2) is an autosomal dominant neurologic disorder characterized by onset of tremor affecting the fingers, hand, and voice in adolescence or young adulthood with somewhat later onset of rhythmic myoclonic jerks and generalized tonic-clonic seizures. Electrophysiologic studies are consistent with cortical reflex myoclonus. Some patients may show cognitive decline or migraines; photosensitivity is common (summary by De Fusco et al., 2014; Crompton et al., 2012). For a phenotypic description and a discussion of genetic heterogeneity of familial adult myoclonic epilepsy, see FAME1 (601068).
Torsion dystonia 13
MedGen UID:
335918
Concept ID:
C1843264
Disease or Syndrome
DYT13 type primary dystonia has characteristics of focal or segmental dystonia with cranial, cervical, or upper limb involvement. It has been reported in individuals from three generations of one large Italian family. Age of onset varied between 5 years and adulthood. The clinical manifestations were generally mild and slowly progressive. The causative gene locus has been identified on chromosome 1p36.13-1p36.32. Transmitted in an autosomal dominant manner.
Early-onset generalized limb-onset dystonia
MedGen UID:
338823
Concept ID:
C1851945
Disease or Syndrome
DYT1 early-onset isolated dystonia typically presents in childhood or adolescence and only on occasion in adulthood. Dystonic muscle contractions causing posturing or irregular tremor of a leg or arm are the most common presenting findings. Dystonia is usually first apparent with specific actions such as writing or walking. Over time, the contractions frequently (but not invariably) become evident with less specific actions and spread to other body regions. No other neurologic abnormalities are present. Disease severity varies considerably even within the same family. Isolated writer's cramp may be the only sign.
Autosomal recessive early-onset Parkinson disease 7
MedGen UID:
344049
Concept ID:
C1853445
Disease or Syndrome
Parkinson's disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.\n\nOften the first symptom of Parkinson's disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson's disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.\n\nParkinson's disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson's disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.\n\nGenerally, Parkinson's disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson's disease.
Neuroferritinopathy
MedGen UID:
381211
Concept ID:
C1853578
Disease or Syndrome
Neuroferritinopathy is an adult-onset progressive movement disorder characterized by chorea or dystonia and speech and swallowing deficits. The movement disorder typically affects one or two limbs and progresses to become more generalized within 20 years of disease onset. When present, asymmetry in the movement abnormalities remains throughout the course of the disorder. Most individuals develop a characteristic orofacial action-specific dystonia related to speech that leads to dysarthrophonia. Frontalis overactivity and orolingual dyskinesia are common. Cognitive deficits and behavioral issues become major problems with time.
Torsion dystonia 2
MedGen UID:
346511
Concept ID:
C1857093
Disease or Syndrome
Torsion dystonia-2 (DYT2) is an autosomal recessive neurologic disorder characterized by onset of symptoms in childhood or adolescence. 'Dystonia' is characterized by involuntary, sustained muscle contractions affecting 1 or more sites of the body; 'torsion' refers to the twisting nature of body movements observed in dystonia. DYT2 first affects distal limbs and later involves the neck, orofacial, and craniocervical regions. DYT2 is slowly progressive but mild overall (summary by Muller and Kupke, 1990; Nemeth, 2002; Khan et al., 2003).
Torsion dystonia 7
MedGen UID:
355560
Concept ID:
C1865818
Disease or Syndrome
Idiopathic torsion dystonia (ITD) is a clinically and genetically heterogeneous group of movement disorders characterized by sustained dystonic muscle contractions causing involuntary twisting movements and/or postures, where causes such as cerebral lesions (especially of the basal ganglia), drugs, or other neurologic disorders have not been found. Adult-onset torsion dystonia usually remains focal and is localized in the upper part of the body (summary by Leube et al., 1996).
Dystonia 21
MedGen UID:
482866
Concept ID:
C3281236
Disease or Syndrome
Dystonia-21 (DYT21) is an autosomal dominant form of pure torsion dystonia, a movement disorder characterized by sustained muscle contractions causing twisting and repetitive movements and abnormal postures (summary by Norgren et al., 2011).
Dystonia 24
MedGen UID:
767288
Concept ID:
C3554374
Disease or Syndrome
Dystonia-24 is an autosomal dominant form of focal dystonia affecting the neck, laryngeal muscles, and muscles of the upper limbs (summary by Charlesworth et al., 2012).
Myoclonic dystonia 26
MedGen UID:
904244
Concept ID:
C4225341
Disease or Syndrome
Myoclonic dystonia-26 (DYT26) is an autosomal dominant neurologic disorder characterized by onset of myoclonic jerks affecting the upper limbs in the first or second decade of life. The disorder is progressive, and patients later develop dystonia with predominant involvement of the craniocervical regions and sometimes the trunk and/or lower limbs. Dystonia dominates the clinical picture (summary by Mencacci et al., 2015).
Developmental and epileptic encephalopathy, 29
MedGen UID:
908570
Concept ID:
C4225361
Disease or Syndrome
Developmental and epileptic encephalopathy-29 (DEE29) is an autosomal recessive neurologic disorder characterized by the onset of refractory myoclonic seizures in the first months of life. Affected individuals have poor overall growth, congenital microcephaly with cerebral atrophy and impaired myelination on brain imaging, spasticity with abnormal movements, peripheral neuropathy, and poor visual fixation (summary by Simons et al., 2015). For a general phenotypic description and a discussion of genetic heterogeneity of DEE, see 308350.
Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities
MedGen UID:
934601
Concept ID:
C4310634
Disease or Syndrome
MECR-related neurologic disorder is characterized by a progressive childhood-onset movement disorder and optic atrophy; intellect is often – but not always – preserved. The movement disorder typically presents between ages one and 6.5 years and is mainly dystonia that can be accompanied by chorea and/or ataxia. Over time some affected individuals require assistive devices for mobility. Speech fluency and intelligibility are progressively impaired due to dysarthria. Optic atrophy typically develops between ages four and 12 years and manifests as reduced visual acuity, which can include functional blindness (also known as legal blindness) in adulthood. Because only 13 affected individuals are known to the authors, and because nearly half of them were diagnosed retrospectively as adults, the natural history of disease progression and other aspects of the phenotype have not yet been completely defined.
Blepharospasm, benign essential, susceptibility to
MedGen UID:
1640286
Concept ID:
C4692845
Finding

Professional guidelines

PubMed

Kępczyńska K, Domitrz I
Toxins (Basel) 2022 Sep 5;14(9) doi: 10.3390/toxins14090619. PMID: 36136557Free PMC Article
Hassell TJW, Charles D
Toxins (Basel) 2020 Apr 22;12(4) doi: 10.3390/toxins12040269. PMID: 32331272Free PMC Article
Katz BJ, Digre KB
Surv Ophthalmol 2016 Jul-Aug;61(4):466-77. Epub 2016 Feb 12 doi: 10.1016/j.survophthal.2016.02.001. PMID: 26875996

Recent clinical studies

Etiology

Kępczyńska K, Domitrz I
Toxins (Basel) 2022 Sep 5;14(9) doi: 10.3390/toxins14090619. PMID: 36136557Free PMC Article
Fagan M, Scorr L, Bernhardt D, Hess EJ, Perlmutter JS, Pardo CA, Jinnah HA
Exp Neurol 2021 Dec;346:113855. Epub 2021 Aug 28 doi: 10.1016/j.expneurol.2021.113855. PMID: 34464652Free PMC Article
Girard B, Davoudi O, Tatry M, Tassart M
J Fr Ophtalmol 2021 Jan;44(1):e1-e12. Epub 2020 Dec 23 doi: 10.1016/j.jfo.2020.11.001. PMID: 33349487
Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A
Mov Disord 2017 Apr;32(4):498-509. Epub 2017 Feb 10 doi: 10.1002/mds.26934. PMID: 28186662Free PMC Article
Evatt ML, Freeman A, Factor S
Handb Clin Neurol 2011;100:481-511. doi: 10.1016/B978-0-444-52014-2.00037-9. PMID: 21496604

Diagnosis

Blitzer AL, Phelps PO
Dis Mon 2020 Oct;66(10):101041. Epub 2020 Jul 1 doi: 10.1016/j.disamonth.2020.101041. PMID: 32622683
Katz BJ, Digre KB
Surv Ophthalmol 2016 Jul-Aug;61(4):466-77. Epub 2016 Feb 12 doi: 10.1016/j.survophthal.2016.02.001. PMID: 26875996
Ko F, Papadopoulos M, Khaw PT
Prog Brain Res 2015;221:177-89. Epub 2015 Sep 9 doi: 10.1016/bs.pbr.2015.06.005. PMID: 26518078
LeDoux MS
Parkinsonism Relat Disord 2012 Jan;18 Suppl 1(Suppl 1):S162-4. doi: 10.1016/S1353-8020(11)70050-5. PMID: 22166421Free PMC Article
Coscarelli JM
Semin Ophthalmol 2010 May;25(3):104-8. doi: 10.3109/08820538.2010.488564. PMID: 20590421

Therapy

Blitzer AL, Phelps PO
Dis Mon 2020 Oct;66(10):101041. Epub 2020 Jul 1 doi: 10.1016/j.disamonth.2020.101041. PMID: 32622683
Hassell TJW, Charles D
Toxins (Basel) 2020 Apr 22;12(4) doi: 10.3390/toxins12040269. PMID: 32331272Free PMC Article
Yen MT
Int Ophthalmol Clin 2018 Winter;58(1):1. doi: 10.1097/IIO.0000000000000210. PMID: 29239872
Wagle Shukla A, Malaty IA
Semin Neurol 2017 Apr;37(2):193-204. Epub 2017 May 16 doi: 10.1055/s-0037-1602246. PMID: 28511260
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA
Neurology 2016 May 10;86(19):1818-26. Epub 2016 Apr 18 doi: 10.1212/WNL.0000000000002560. PMID: 27164716Free PMC Article

Prognosis

Lee SM, Wu J, Hwang DD
Korean J Ophthalmol 2023 Jun;37(3):255-265. Epub 2023 Apr 17 doi: 10.3341/kjo.2022.0111. PMID: 37068839Free PMC Article
Tranchant C, Koob M, Anheim M
Parkinsonism Relat Disord 2017 Jun;39:4-16. Epub 2017 Feb 22 doi: 10.1016/j.parkreldis.2017.02.025. PMID: 28256436
Naumann M, Boo LM, Ackerman AH, Gallagher CJ
J Neural Transm (Vienna) 2013 Feb;120(2):275-90. Epub 2012 Sep 25 doi: 10.1007/s00702-012-0893-9. PMID: 23008029Free PMC Article
Brasić JR, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, Klutchko B, Cancro R, Sheitman BB, Buchsbaum M, Brathwaite C
Psychol Rep 1999 Feb;84(1):239-46. doi: 10.2466/pr0.1999.84.1.239. PMID: 10203957
Harrison MS
J Laryngol Otol 1976 Jun;90(6):561-70. doi: 10.1017/s0022215100082451. PMID: 778316

Clinical prediction guides

Brin MF, Blitzer A
Medicine (Baltimore) 2023 Jul 1;102(S1):e32373. doi: 10.1097/MD.0000000000032373. PMID: 37499079Free PMC Article
Gamain J, Herr T, Fleischmann R, Stenner A, Vollmer M, Willert C, Veit B, Lehnert B, Mueller JU, Steigerwald F, Tost F, Kronenbuerger M
J Neural Transm (Vienna) 2021 Aug;128(8):1215-1224. Epub 2021 Jun 28 doi: 10.1007/s00702-021-02366-4. PMID: 34184129Free PMC Article
Toxicol Ind Health 2019 Mar;35(3):204-210. doi: 10.1177/0748233719825529. PMID: 30862300
Jost WH, Benecke R, Hauschke D, Jankovic J, Kaňovský P, Roggenkämper P, Simpson DM, Comella CL
Drug Des Devel Ther 2015;9:1913-26. Epub 2015 Apr 1 doi: 10.2147/DDDT.S79193. PMID: 25897202Free PMC Article
Naumann M, Boo LM, Ackerman AH, Gallagher CJ
J Neural Transm (Vienna) 2013 Feb;120(2):275-90. Epub 2012 Sep 25 doi: 10.1007/s00702-012-0893-9. PMID: 23008029Free PMC Article

Recent systematic reviews

McCambridge AB, Bradnam LV
Eur J Neurosci 2021 Feb;53(4):1300-1323. Epub 2020 Oct 27 doi: 10.1111/ejn.14987. PMID: 32991762
Rayess YA, Awaida CJ, Jabbour SF, Ballan AS, Sleilati FH, Abou Zeid SM, Nasr MW
Rev Neurol (Paris) 2021 Jan-Feb;177(1-2):107-114. Epub 2020 Jul 9 doi: 10.1016/j.neurol.2020.03.022. PMID: 32654779
Tranchant C, Koob M, Anheim M
Parkinsonism Relat Disord 2017 Jun;39:4-16. Epub 2017 Feb 22 doi: 10.1016/j.parkreldis.2017.02.025. PMID: 28256436
Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A
Mov Disord 2013 Jun 15;28(7):874-83. doi: 10.1002/mds.25579. PMID: 23893443Free PMC Article
Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T
Mov Disord 2012 Dec;27(14):1789-96. Epub 2012 Oct 31 doi: 10.1002/mds.25244. PMID: 23114997

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...